Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nephrol Dial Transplant. 2014 May 8. [Epub ahead of print]

To TDM or not to TDM in lupus nephritis patients treated with MMF?

Author information

  • 1Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands.

Abstract

Mycophenolic acid (MPA) has become the cornerstone in the treatment of lupus nephritis. However, response rates are still far from ideal in clinical trials. Uncertainty exists regarding the correct dosing of MPA, and the recommended doses vary between recently published guidelines. Side effects are an additional problem resulting in frequent dose reduction and possible suboptimal exposure.In this review, we discuss the large variability between patients in drug exposure to MPA and the evidence for a relationship between drug exposure and efficacy in lupus nephritis. Methods for drug monitoring of MPA are discussed, and based on the current literature, we suggest as potential target levels a pre-dose level of 3.0 mg/L and an area under the concentration-versus-time curve between 35 and 45 mg h/L.Therapeutic drug monitoring may improve response rates in lupus nephritis by preventing low exposure and at the same time may reduce unnecessary side effects in patients who have high drug exposure with standard dose MPA. We specifically advise assessment of MPA drug exposure early after start of treatment and before concluding that treatment with MPA has failed.

KEYWORDS:

AUC; lupus nephritis; mycophenolate mofetil; mycophenolic acid; therapeutic drug monitoring

PMID:
24811231
[PubMed - as supplied by publisher]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk